EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Personnel Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board. 21.11.2023 / 15:26 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, November 21, 2023. Dr. Hakim Bouterfa, Executive Board member of Eckert & Ziegler AG and responsible for clinical development, will leave the Executive Board of Eckert & Ziegler AG at the end of the year and in future will concentrate exclusively on his tasks as Executive Board member of the Eckert & Ziegler subsidiary Pentixapharm AG (PTX). There he will be supported by Dr. Dirk Pleimes and Anna Steeger, who have been newly appointed to the Executive Board of Pentixapharm AG. Following the consolidation of all clinical activities of the Eckert & Ziegler Group within or below PTX in recent months and following the decision to split-off PTX from the Group, Eckert & Ziegler AG no longer requires the position for clinical development within the Executive Board. The founder and Chairman of the Supervisory Board of Eckert & Ziegler AG, Dr. Andreas Eckert, will resign from the Supervisory Board in spring 2024 to also join the Executive Board of Pentixapharm AG. He will accompany the announced split-off. The management of Pentixapharm AG will present an overview of the split-off plans and corresponding measures to the shareholders of Eckert & Ziegler AG on November 27, 2023 at 6 p.m. at the German Equity Forum in Frankfurt, www.eigenkapitalforum.com. About Eckert & Ziegler. Your contact: 21.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
EnGene’s $60M PIPE; AbbVie to develop neuropsychiatric drugs with Gedeon Richter
Plus, news about Tectonic Therapeutic, Molecular Partners and Arcus Biosciences: EnGene snags $60M: The Boston and Montreal gene therapy biotech Sign up to read this